This well-conducted review assessed the effects of omega-3 fatty acids on cancer risk. The authors concluded that there is no evidence to suggest that there is a significant association between omega-3 fatty acids and cancer incidence. The authors' conclusions are likely to be reliable.
Participants included in the review
Studies that included human participants were eligible for inclusion in the review; no further details were provided. There was a wide variety of participants in the studies: Caucasian, black and Asian participants with birth years ranging from 1880 to 1974. Both males and females with a wide range of cancers were included.
Outcomes assessed in the review
Studies that included a description of the effects of omega-3 fatty acids on tumour incidence were eligible for inclusion; no further details were provided. The studies included in the review reported tumour incidence for eleven types of cancer, with over half reporting on breast, colorectal or prostate cancer.
How were decisions on the relevance of primary studies made?
Two reviewers independently evaluated the titles and abstracts of primary studies. Any disagreements were resolved through consensus.
Assessment of study quality
Information relating to the ascertainment of cases and exposure, description of withdrawals and drop-outs, adjustment for confounders, and blinded assessment of exposure and case status of the included observational studies was recorded.
No scores of quality were calculated. Two reviewers independently extracted data on the quality of the included studies. 
Data extraction
Two reviewers independently abstracted the data onto a detailed summary table. Any differences were resolved through consensus, with disagreements referred to a third reviewer. For each of the studies, the multivariate-adjusted risk ratios (RRs) reported for the group with the highest reported intake of omega-3 fatty acids relative to the group with the lowest reported intake of omega-3 fatty acids were presented.
Methods of synthesis
How were the studies combined?
The studies were presented in a narrative synthesis, owing to heterogeneity between the identified studies.
How were differences between studies investigated?
Plots of the point estimates of the RRs weighted according to the inverse of the variance were produced in order to assess the possible effects of sample size. The study results were presented according to type of cancer and were discussed in terms of type of omega-3 fatty acid.
Results of the review
Twenty different cohort studies were identified. These ranged in size from 6,000 to 121,000 participants with 9,000 to 1.5 million person-years of observation, with a total of over 700,000 participants and 3 million person-years of observation.
All of the included cohort studies were of variable quality. Qualitative and visual evaluation suggests that there were no differences in reported risks based on sample size.
Breast cancer (8 studies, n=412,134): one study found that there was an increased risk of breast cancer for women in the highest quartile of fish consumption compared with women in the lowest quartile (incidence RR 1.47, 95% confidence interval, CI: 1.10, 1.98). Two studies found that there was a reduced risk for women consuming larger amounts of fish or marine omega-3 than for women with lower consumption: the RRs were 0.77 (95% CI: 0.60, 0.98) and 0.72 (95% CI: 0.53, 0.98), respectively. None of the other studies found associations between breast cancer and omega-3 consumption. One study reported a reduced risk of breast cancer for women in the highest quintile of ALA consumption compared with women in the lowest quintile (RR 0.70, 95% CI: 0.51, 0.97), but no associations between EPA or DHA consumption and breast cancer risk.
Colorectal cancer (9 studies (7 cohorts), n=391,376): one study suggested that there was a reduced risk of colorectal cancer for those in the highest quartile of fish intake compared with those in the lowest quartile (RR 0.49, 95% CI: 0.27, 0.89). One study suggested a trend for a reduction in risk for those with higher consumption of omega-3 when adjusting for age. None of the other studies demonstrated associations between colorectal cancer risk and omega-3 consumption.
Lung cancer (n=151,987): of the 3 studies that evaluated the relationship between lung cancer and omega-3 intake through fish consumption, one suggested an increased risk of lung cancer (incidence RR 3.0, 95% CI: 1.2, 7.3), one suggested a reduced risk of lung cancer (RR 0.32, 95% CI: 0.13, 0.76), and the third showed no association.
Prostate cancer (7 studies (5 cohorts), at least n=129,255): one study found that there was a reduced risk of prostate cancer for men that never or seldom ate fish compared with those with moderate consumption (RR 2.3, 95% CI: 1.2, 4.5), one study showed a trend towards a similar effect, and two found no association. One study reported an increased risk of prostate cancer for men in the highest quintile of ALA consumption compared with men in the lowest quintile (RR 1.98, 95% CI: 1.34, 2.93). No association was found between prostate cancer risk and EPA, DHA or marine omega-3 consumption in the same study.
Skin cancer (n=64,779): one study was identified. This demonstrated an increase in the risk of basal cell carcinoma for those in the highest quartile of omega-3 fat consumption compared with those in the lowest quartile of consumption (RR 1.13, 95% CI: 1.01, 1.27).
No significant associations between omega-3 fatty acids and cancer risk were found with regards to aerodigestive 
